Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer in men in the western world. Mutations in tumor suppressor genes and in oncogenes are important for PCa progression, whereas the role of stem cell proteins in...
Junshi Biosciences and Coherus Biosciences announced the initiation of the rolling submission of the Biologics License Application for toripalimab to the FDA for the treatment of recurrent or metastatic nasopharyngeal carcinoma.
Combining Avastin (bevacizumab), from Roche/Genentech, with standard chemoradiation therapy is safe and could prolong survival in patients with advanced Nasopharyngeal...
This guideline covers identifying and caring for adults who are malnourished or at risk of malnutrition in hospital or in their own home or a care home.
BeiGene announced that the China National Medical Products Administration (NMPA) has approved BeiGene’s anti-PD-1 antibody, tislelizumab, in combination with chemotherapy as a first-line treatment for patients with recurrent or metastatic nasopharyngeal cancer (NPC).
Shanghai Junshi Biosciences and Coherus Biosciences announced the completion of the rolling submission of the Biologics License Application to the FDA for Tuoyi (toripalimab) in combination with gemcitabine and cisplatin for first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal carcinoma and toripalimab monotherapy for second-line or above treatment of recurrent or metastatic NPC after platinum-containing chemotherapy.
Shanghai Junshi Biosciences announced that the National Medical Products Administration (NMPA) of China has granted a conditional approval to toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) after failure of at least two lines of prior systemic therapy.
Shanghai Junshi Biosciences and Coherus BioSciences announced the results of the prespecified final progression-free survival analysis and the interim overall survival analysis of the JUPITER-02 study (NCT03581786), a pivotal Phase III trial in first-line treatment of recurrent or metastatic nasopharyngeal carcinoma using Tuoyi (toripalimab).
BeiGene, Ltd. announced that the Phase III RATIONALE 309 trial of its anti-PD-1 antibody tislelizumab combined with chemotherapy versus placebo combined with chemotherapy as a first-line treatment for patients with recurrent or metastatic nasopharyngeal cancer (NPC) met its primary endpoint of progression-free survival (PFS) at the interim analysis, as recommended by an independent data monitoring committee.
This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support.